Opioids Market Overview to 2023 - Opioids in Emerging Markets
|発行||CBR Pharma Insights||商品コード||320841|
|出版日||ページ情報||英文 72 Pages
|オピオイド市場の概要：新興市場のオピオイド Opioids Market Overview to 2023 - Opioids in Emerging Markets|
|出版日: 2014年11月30日||ページ情報: 英文 72 Pages||
The report provides analysis of new developments that will have a strong bearing on the use of opioids in pain management in emerging countries (Argentina, Brazil, China, India, Mexico, Russia and South Africa). Access to opioids is restricted under strict drug control policies and regulations overseeing controlled medicines due to their high abuse potential. Emphasis on restricting access to controlled drugs is much higher in emerging markets than in developed nations, resulting in a level of consumption that is too low to meet pain-control requirements even in cases of terminal illness. There is a high level of unmet need for pain control in both cancer and HIV/AIDS, and serious concerns have been raised regarding inadequate pain management in the emerging markets.
However, this is expected to change in the near future as regulatory authorities attempt to remedy the situation. Indeed, several new developments promise a better outlook for future access. Although India currently has a minor share of the market, it is expected to post a high growth rate (21.3% by 2023) due to improved access to opioid analgesics. Similarly, consumption in Brazil and Argentina is also expected to increase due to recent changes to their palliative care policies. Although the opioids market in emerging countries is small, it is expected to grow at a faster pace in forecast period than in some developed countries.
"Opioids in Emerging Markets covers" the major emerging markets of Argentina, Brazil, China, India, Mexico, Russia, and South Africa, and includes -